I-Mab Stock Price, News & Analysis

I-Mab (Nasdaq: IMAB) has announced positive topline results from its Phase 2 clinical study of olamkicept for treating active ulcerative colitis (UC). This randomized, double-blind trial showed that patients receiving 600 mg olamkicept biweekly had significantly higher clinical response rates after 12 weeks compared to placebo (p=0.032). Key secondary endpoints, including clinical remission and mucosal healing, were also met (p<0.001). The drug demonstrated a favorable safety profile. I-Mab aims to expand olamkicept's market reach, exploring collaborations in the U.S., Canada, and Europe.

I-Mab (Nasdaq: IMAB) has announced that its abstract on the CD73 antibody, uliledlimab, has been selected for a poster presentation at the 2021 ASCO Annual Meeting scheduled for June 4-8, 2021. This antibody is designed to modulate the tumor microenvironment and enhance anti-tumor responses, particularly when combined with PD-(L)1 inhibitors. Preliminary clinical studies have shown that uliledlimab is safe and well tolerated, demonstrating clinical activity in patients with advanced solid tumors. Further research is ongoing to validate its efficacy.

I-Mab (Nasdaq: IMAB) and ABL Bio (Kosdaq: 298380) announce the dosing of the first patient in a Phase 1 trial for bispecific antibody TJ-L14B/ABL503. This trial aims to assess the safety and efficacy of the antibody in treating locally advanced or metastatic solid tumors (NCT04762641). Developed using ABL's 'Grabody-T' technology, the bispecific antibody targets PD-L1 and engages T-cell activation to enhance antitumor activity while reducing off-tumor toxicity. Initial results suggest improved efficacy over traditional treatments.

I-Mab (Nasdaq: IMAB) announced its participation in several key conferences in April 2021, showcasing its commitment to advancing immuno-oncology therapeutics. Notable events include the 20th Annual Needham Healthcare Conference and the 2021 Haitong Securities Spring Listed Companies Conference, where management presentations by key executives such as Dr. Jingwu Zang and Ms. Leah Liu will take place. The company continues to evolve from a clinical-stage biotech entity to a fully integrated global biopharmaceutical company, with a robust pipeline of over 15 drug candidates.

I-Mab (Nasdaq: IMAB) and ABL Bio, Inc. have received FDA approval for their Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for the bispecific antibody TJ-CD4B/ABL111. This trial aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of TJ-CD4B/ABL111 in patients with advanced or metastatic solid tumors. The antibody targets Claudin 18.2, enhancing immune response specifically at tumor sites while minimizing side effects. Both companies are optimistic about advancing this promising therapeutic option.

I-Mab (Nasdaq: IMAB) announced robust full-year results for 2020, achieving net revenues of RMB 1,542.7 million (US $236.4 million) and corporate profitability. Notably, the company has made significant strides in its clinical pipeline, achieving 18 milestones since its IPO, with three registrational trials currently underway. The New Drug Application for felzartamab (TJ202) is on track for submission in 2021. A global collaboration with AbbVie aims to advance the CD47 antibody lemzoparlimab (TJC4). The company holds a total cash position of RMB 4.8 billion (US $734.1 million), supporting operations through 2023.

I-Mab (Nasdaq: IMAB) will host its 2021 R&D Day with two sessions: a Mandarin session on April 7, 2021, at 14:00 CST, and an English session on April 26, 2021, from 8:00 am to 11:00 am EDT. Key presentations will feature Dr. Jingwu Zang and Dr. Joan Shen, focusing on I-Mab’s pipeline programs and R&D strategy. Investors can join via a live webcast available on the company’s Investor Relations site. I-Mab is transitioning into a fully integrated global biopharma company with over 15 clinical and pre-clinical stage candidates in the immuno-oncology sector.

I-Mab (Nasdaq: IMAB) announced the filing of a prospectus supplement with the SEC to register 19,050,555 ordinary shares held by Gaoling Fund and YHG Investment, in compliance with PIPE Agreements from September 2020. Hillhouse currently owns 13.3% of I-Mab's shares. This registration is part of a shelf registration statement filed on February 5, 2021. I-Mab, a clinical-stage biopharmaceutical company, focuses on immuno-oncology and has a pipeline of over 15 drug candidates, aiming for transformational medicines through innovative drug development.

I-Mab (NASDAQ: IMAB) announced a poster presentation at the 2021 AACR Annual Meeting showcasing uliledlimab (TJD5), a novel CD73 blocking antibody. This innovative treatment targets adenosine-rich cancer microenvironments with unique binding properties, providing potential anti-tumor activity in combination with PD-(L)1 therapies. Additionally, an abstract has been submitted for the phase 1 study of uliledlimab and atezolizumab, indicating ongoing clinical evaluation. The meeting will occur virtually from April 10-15, 2021.